期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到6,361篇文章
< 1 2 … 250 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation:Insights from whole exome sequencing 认领 引用
1
作者 Xu Wang Long Jin +3 位作者 Xinlin Zou Ankang Zhu Mingyu Li Haitao Fan 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2026年第1期281-298,共18页
This study investigates the role of ERBB2 mutations in promoting recurrence and metastasis of non-muscle-invasive bladder cancer(NMIBC).Analysis of whole exome sequencing(WES)data from The Cancer Genome Atlas(TCGA)and... This study investigates the role of ERBB2 mutations in promoting recurrence and metastasis of non-muscle-invasive bladder cancer(NMIBC).Analysis of whole exome sequencing(WES)data from The Cancer Genome Atlas(TCGA)and the International Cancer Genome Consortium(ICGC)databases revealed a significant association between ERBB2 mutations and immune cell infiltration.To validate these findings,formalin-fixed,paraffin-embedded tumor tissues from patients with recurrent NMIBC were analyzed,with a focus on ERBB2 mutations.In addition,bladder cancer cell lines carrying wild type or mutant ERBB2 were established using clustered regularly interspaced short palindromic repeats(CRISPR)-associated protein 9(CRISPR/Cas9)technology.Functional experiments,including Western blotting,protein stability assays,and ubiquitination analyses,demonstrated that ERBB2 mutations promote hypoxia-inducible factor-1(HIF-1)phosphorylation,leading to its stabilization and enhancing the proliferative,migratory,and invasive capacities of tumor cells.Furthermore,flow cytometry,5-ethynyl-2′-deoxyuridine(EdU),Cell Counting Kit-8(CCK-8),and Transwell assays confirmed the impact of these mutations on cellular behavior,while drug sensitivity assays indicated increased susceptibility of ERBB2-mutant cells to therapeutic agents.In vivo studies using mouse models further supported these findings,showing that ERBB2 mutations promote tumor growth,metastasis,and macrophage infiltration.Collectively,these results suggest that ERBB2 mutations drive NMIBC progression by stabilizing HIF-1 through phosphorylation,thereby facilitating tumor development and immune modulation,and underscore the potential of ERBB2 as a therapeutic target for preventing NMIBC recurrence and metastasis. 展开更多
关键词 Whole exome sequencing Non-muscle-invasive bladder cancer Bioinformatics ERBB2 HIF-1 Phosphorylation Proliferation Metastasis
暂未订购 下载PDF
Recurrence and prevention strategies for non-muscle-invasive bladder cancer:A comprehensive review 认领 引用
2
作者 Wuhao Liu Jiafu Xiao +1 位作者 Junrong Zou Zhihua He 《Asian Journal of Urology》 CAS CSCD 2026年第1期11-23,共13页
Objective:This review aims to explore the risk factors for recurrence of nonmuscle-invasive bladder cancer(NMIBC)and evaluate current prevention strategies to provide valuable insights for future clinical management.B... Objective:This review aims to explore the risk factors for recurrence of nonmuscle-invasive bladder cancer(NMIBC)and evaluate current prevention strategies to provide valuable insights for future clinical management.By systematically analyzing various clinical and pathological characteristics,this review examines their relationship with NMIBC recurrence and proposes effective preventive measures for these factors.Methods:A systematic literature search was conducted through PubMed and Web of Science to identify studies that focus on the risk factors for NMIBC recurrence.A systematic review was conducted to evaluate the statistical significance of various factors influencing recurrence,such as age,sex,body mass index(BMI),diabetes,smoking,surgical techniques,and tumorspecific characteristics.Additionally,current preventive strategies and treatments,such as intravesical drug instillation,adjuvant chemotherapy,and immunotherapy,were assessed.Results:The following factors significantly influence the recurrence risk of NMIBC:age(older patients have a higher recurrence risk due to weakened immune responses and more comorbidities),sex(women tend to experience more aggressive forms and a poorer prognosis following recurrence),BMI and diabetes(obesity and diabetes worsen immune responses and increase inflammation,contributing to higher recurrence rates),smoking(smokers face a higher recurrence risk due to carcinogenic exposure,but quitting significantly reduces the risk),surgical techniques(incomplete transurethral resection of bladder tumor or inadequate postoperative treatments,e.g.,Bacillus Calmette-Guerin[BCG],increase recurrence),tumor characteristics(high-grade and large tumors[especially multifocal]have a higher risk of recurrence),immunotherapy and chemotherapy(BCG is standard for high-risk patients,while newer treatments,such as immune checkpoint inhibitors[e.g.,pembrolizumab]and chemotherapy[e.g.,gemcitabine with docetaxel],are emerging for BCG-unresponsive cases),and biomarkers(biomarkers like tumor DNA in urine or circulating tumor DNA in blood can facilitate early detection of recurrence and help predict recurrence risk). 展开更多
关键词 Non-muscle-invasive bladder cancer Recurrence Risk factors Prevention
暂未订购 下载PDF
Survival outcomes with pelvic node dissection after partial cystectomy among octogenarians with muscle-invasive bladder cancer 认领 引用
3
作者 Arjun Pon Avudaiappan Pushan Prabhakar +4 位作者 Hannah Baker Mukesh K.Roy Manuel Ozambela Jr Christopher Gomez Murugesan Manoharan 《The Canadian Journal of Urology》 SCIE 2025年第3期137-143,共7页
Introduction:Radical cystectomy with pelvic node dissection remains the standard of care for muscle-invasive bladder carcinoma(MIBC);however,there is a growing interest in bladder preservation alternatives among the e... Introduction:Radical cystectomy with pelvic node dissection remains the standard of care for muscle-invasive bladder carcinoma(MIBC);however,there is a growing interest in bladder preservation alternatives among the elderly population.Guidelines indicate that partial cystectomy(PC)combined with pelvic node dissection(LND)can be considered as an alternative in carefully selected individuals.Using the National Cancer Database,we analyzed the overall survival(OS)between PC with and without LND among octogenarians.Methods:We identified octogenarians with localized muscle-invasive bladder carcinoma(cT2-3N0M0)and urothelial histology who underwent PC with or without LND between 2004 and 2018.Based on the number of lymph nodes removed(LNR),the LND group was further subdivided into=10 lymph node groups.A propensity-matched Kaplan-Meier survival analysis was performed to compare OS between these groups.Results:Among 2573 patients who underwent PC,492 octogenarians met our selection criteria.208(42.2%)had LND,while 284(57.8%)had no LND.Within the LND group,53(25.5%)had=10 LNR.The median OS for the matched LND and non-LND groups was 36.9 and 33.4 months(p=0.96),respectively.Similarly,=10 LNR had 36.9 and 43.5 months(p=0.42),respectively.Multivariate Cox regression analysis revealed no difference in the risk of mortality.Conclusion:Among octogenarians who underwent PC,there was no significant difference in OS between those with or without LND,and between=10 LNR groups.Therefore,the role and extent of LND after PC need further exploration in this subset of the population. 展开更多
关键词 partial cystectomy pelvic node dissection muscle-invasive bladder cancer elderly octogenarian
暂未订购 下载PDF
A Study on the Current Situation of Supportive Care Needs and Influencing Factors of Postoperative Patients with Muscle-Invasive Bladder Cancer 认领 引用
4
作者 Xue Hu Shangkun Zhang +2 位作者 Qian Sun Juan Zhou Xia Pan 《Journal of Biosciences and Medicines》 2025年第2期357-368,共12页
Objective: To explore the current status and influencing factors of supportive care needs in patients with muscle-invasive bladder cancer after surgery, and to provide a reference for the development of targeted inter... Objective: To explore the current status and influencing factors of supportive care needs in patients with muscle-invasive bladder cancer after surgery, and to provide a reference for the development of targeted intervention strPan ategies. Methods: A general data questionnaire and supportive care needs scale were used to investigate 107 patients with muscle-invasive bladder cancer after surgery. Results: The total score of supportive care needs in patients with muscle-invasive bladder cancer after surgery was (98.48 ± 9.07). Multiple linear regression analysis showed that age, primary caregiver, medical payment method, number of hospitalizations and postoperative time were important influencing factors of supportive care needs in patients with muscle-invasive bladder cancer after surgery (P Conclusion: The supportive care needs of patients with muscle-invasive bladder cancer after surgery are at a low level. Medical staff should identify them early, pay more attention to young patients, patients without medical insurance and patients with multiple hospitalizations, and provide targeted nursing measures to meet their supportive care needs. 展开更多
关键词 Muscle-Invasive Bladder Cancer Supportive Care Needs Influencing Factors
暂未订购 下载PDF
A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer 认领 引用 被引量：5
5
作者 Chinna Babu Dracham Narendra Kumar +6 位作者 Santosh Kumar Arun Elangovan Budhi Singh Yadav Ravimohan S.Mavuduru Anupam Lal Pramod K.Gupta Rakesh Kapoor 《Asian Journal of Urology》 CSCD 2022年第3期318-328,共11页
Objective:Conservative approaches in muscle-invasive bladder cancer(MIBC)have been evolved to avoid aggressive surgery,but are limited to elderly,frail,and patients medically unfit for surgery.Our study aimed to asses... Objective:Conservative approaches in muscle-invasive bladder cancer(MIBC)have been evolved to avoid aggressive surgery,but are limited to elderly,frail,and patients medically unfit for surgery.Our study aimed to assess the response rate of neoadjuvant chemotherapy(NACT)before radiotherapy(RT)in MIBC patients.Methods:Forty patients with urothelial carcinoma of stage T2-T4a,N0,M0 were enrolled between November 2013 and November 2015,and treated with three cycles of NACT with gemcitabine-cisplatin.Post-NACT response was assessed using Response Evaluation Criteria in Solid Tumors(RECIST)criteria.Patients who achieved complete response(CR)and partial response(PR)>50%were treated with radical RT,and those who had PR50%or CR,and were treated with RT.Five(12.5%)patients who had PR<50%,SD,or PD underwent RC.All patients who received radiation showed CR after 6 weeks.Median follow-up was 43 months(range:10-66 months)and median overall survival(OS)was not reached.Three-year OS,local control,and disease-free survival were 70.1%,60.9%,50.6%,respectively,and 50%of patients preserved their functioning bladder.Three-year OS rate was 88.9%in patients who achieved CR to NACT,73.1%in patients with PR≥50%and 40%in patients with PR<50%.Conclusion:NACT followed by RT provides a high probability of local response with bladder preservation in CR patients.Appropriate use of this treatment regimen in carefully selected patients may omit the need for morbid surgery. 展开更多
关键词 Bladder preservation Neoadjuvant chemotherapy Radiotherapy Muscle-invasive bladder cancer
暂未订购 下载PDF
Erectile dysfunction in nonmuscle-invasive bladder cancer patients before and after transurethral resection(TUR)of bladder tumor in China 认领 引用 被引量：1
6
作者 Peng Guo Yu Wang +1 位作者 Yun-Feng Xie Tian-Bing Lv 《Asian Journal of Andrology》 SCIE CAS CSCD 2022年第5期509-512,共4页
The aim of this study was to investigate the incidence of erectile dysfunction(ED)in nonmuscle-invasive bladder cancer(NMIBC)patients before and after transurethral resection(TUR)in China.Clinical data from 165 male p... The aim of this study was to investigate the incidence of erectile dysfunction(ED)in nonmuscle-invasive bladder cancer(NMIBC)patients before and after transurethral resection(TUR)in China.Clinical data from 165 male patients with NMIBC who received adjuvant intravesical chemotherapy after TUR in Neijiang First People’s Hospital(Neijiang,China)between January 2010 and June 2019 were retrospectively reviewed.The sexual function of these patients was evaluated before and 1.5 years after initial TUR by the International Index of Erectile Function-5(IIEF-5).An age-specific subanalysis was performed among the patients:<45 years old(Group 1,n=19)and≥45 years old(Group 2,n=146).Before and 1.5 years after TUR,the incidence rates of ED in Group 1 were 15.8%and 52.6%,and those in Group 2 were 54.1%and 61.0%,respectively.The difference between groups was statistically significant at the preoperative stage(15.8%vs 54.1%,P=0.002)but not at the postoperative stage(52.6%vs 61.0%,P=0.562).Compared with the preoperative stage,the incidence of ED at the postoperative stage was increased significantly in Group 1(15.8%vs 52.6%,P=0.017)but not in Group 2(54.1%vs 61.0%,P=0.345).In conclusion,the incidence of ED increased in male NMIBC patients under the age of 45 years after TUR in China.These patients should be offered professional counseling during the follow-up period. 展开更多
关键词 erectile dysfunction male sexual dysfunction nonmuscle-invasive bladder cancer transurethral resection
暂未订购 下载PDF
A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer 认领 引用 被引量：5
7
作者 Qiang Ruan Degang Ding +13 位作者 Bin Wang Chaohong He Xuequn Ren Zhenhua Feng Zhigang Pang Jin Wang Xiangliang Zhang Hongsheng Tang Jiahong Wang Qingjun He Ziying Lei Quanxing Liao Jiali Luo Shuzhong Cui 《Cancer Biology & Medicine》 SCIE CAS CSCD 2021年第1期308-317,共10页
Objective:To compare the efficacy and safety of hyperthermic intravesical chemotherapy(HIVEC)and intravesical chemotherapy(IVEC)in patients with intermediate and high risk nonmuscle-invasive bladder cancer(NMIBC)after... Objective:To compare the efficacy and safety of hyperthermic intravesical chemotherapy(HIVEC)and intravesical chemotherapy(IVEC)in patients with intermediate and high risk nonmuscle-invasive bladder cancer(NMIBC)after transurethral resection.Methods:We included 560 patients diagnosed with primary or recurrent NMIBC between April 2009 and December 2015 at 1 of 6 tertiary centers.We matched 364 intermediate or high risk cases and divided them into 2 groups:the HIVEC+IVEC group[chemohyperthermia(CHT)composed of 3 consecutive sessions followed by intravesical instillation without hyperthermia]and the IVEC group(intravesical instillation without hyperthermia).The data were recorded in the database.The primary endpoint was 2-year recurrence-free survival(RFS)in all NMIBC patients(n=364),whereas the secondary endpoints were the assessment of radical cystectomy(RC)and 5-year overall survival(OS).Results:There was a significant difference in the 2-year RFS between the two groups in all patients(n=364;HIVEC+IVEC:82.42%vs.IVEC:74.18%,P=0.038).Compared with the IVEC group,the HIVEC+IVEC group had a lower incidence of RC(P=0.0274).However,the 5-year OS was the same between the 2 groups(P=0.1434).Adverse events(AEs)occurred in 32.7%of all patients,but none of the events was serious(grades 3–4).No difference in the incidence or severity of AEs between each treatment modality was observed.Conclusions:This retrospective study showed that HIVEC+IVEC had a higher 2-year RFS and a lower incidence of RC than IVEC therapy in intermediate and high risk NMIBC patients.Both treatments were well-tolerated in a similar manner. 展开更多
关键词 Nonmuscle-invasive bladder cancer intravesical chemotherapy hyperthermia chemohyperthermia retrospective study
暂未订购 下载PDF
Treatment and surveillance for non-muscle-invasive bladder cancer:a clinical practice guideline(2021 edition) 认领 引用 被引量：22
8
作者 Ying-Hui Jin Xian-Tao Zeng +31 位作者 Tong-Zu Liu Zhi-Ming Bai Zhong-Ling Dou De-Gang Ding Zhi-Lu Fan Ping Han Yi-Ran Huang Xing Huang Ming Li Xiao-Dong Li Yi-Ning Li Xu-Hui Li Chao-Zhao Liang Jiu-Min Liu Hong-Shun Ma Juan Qi Jia-Qi Shi Jian Wang De-Lin Wang Zhi-Ping Wang Yun-Yun Wang Yong-Bo Wang Qiang Wei Hai-Bo Xia Jin-Chun Xing Si-Yu Yan Xue-Pei Zhang Guo-You Zheng Nian-Zeng Xing Da-Lin He Xing-Huan Wang the Chinese Urological Doctor Association,Urological Association of Chinese Research Hospital Association,Uro-Health Promotive Association of China International Exchange,Promotive Association for Medical,Health Care 《Military Medical Research》 SCIE CAS CSCD 2023年第2期141-161,共21页
Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease burden.Treatment and surveillance are the most important part of NIMBC management... Non-muscle invasive bladder cancer(NMIBC)is a major type of bladder cancer with a high incidence worldwide,resulting in a great disease burden.Treatment and surveillance are the most important part of NIMBC management.In 2018,we issued“Treatment and surveillance for non-muscle-invasive bladder cancer in China:an evidencebased clinical practice guideline”.Since then,various studies on the treatment and surveillance of NMIBC have been published.There is a need to incorporate these materials and also to take into account the relatively limited medical resources in primary medical institutions in China.Developing a version of guideline which takes these two issues into account to promote the management of NMIBC is therefore indicated.We formed a working group of clinical experts and methodologists.Through questionnaire investigation of clinicians including primary medical institutions,24 clinically concerned issues,involving transurethral resection of bladder tumor(TURBT),intravesical chemotherapy and intravesical immunotherapy of NMIBC,and follow-up and surveillance of the NMIBC patients,were determined for this guideline.Researches and recommendations on the management of NMIBC in databases,guideline development professional societies and monographs were referred to,and the European Association of Urology was used to assess the certainty of generated recommendations.Finally,we issued 29 statements,among which 22 were strong recommendations,and 7 were weak recommendations.These recommendations cover the topics of TURBT,postoperative chemotherapy after TURBT,Bacillus Calmette–Guérin(BCG)immunotherapy after TURBT,combination treatment of BCG and chemotherapy after TURBT,treatment of carcinoma in situ,radical cystectomy,treatment of NMIBC recurrence,and follow-up and surveillance.We hope these recommendations can help promote the treatment and surveillance of NMIBC in China,especially for the primary medical institutions. 展开更多
关键词 Non-muscle invasive bladder cancer Bladder cancer Transurethral resection of bladder tumor Treatment Surveillance Guideline
暂未订购 下载PDF
Long-term versus Short-term Introvesical Chemotherapy in Patients with Non-muscle-invasive Bladder Cancer:A Systematic Review and Meta-analysis of the Published Results of Randomized Clinical Trials 认领 引用 被引量：1
9
作者 李腾 行怡 +3 位作者 刘述成 韩晓敏 李文成 陈敏 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 2014年第5期706-715,共10页
In order to assess the effect of long-term versus short-term intravesical chemotherapy in preventing the recurrence of patients with non-muscle-invasive bladder cancer, we searched several da- tabases with words as me... In order to assess the effect of long-term versus short-term intravesical chemotherapy in preventing the recurrence of patients with non-muscle-invasive bladder cancer, we searched several da- tabases with words as mesh terms and free text words to find all eligible randomized clinical trials （RCTs） for the Comparison of the two strategies of instillation durations. ＂Observed-Expected events re- search （O-E）＂ and ＂Variance （V）＂ for calculating hazard ratio （HR） were used in Revman 5.2 software recommended by Cochrane Collabration for data analysis. Sensitivity and subgroup analysis were se- lected to minish heterogeneity. GRADEpro 3.6 profile recommended by Cochrane Collabration was employed for quality assessment of analyses. Finally, 13 eligible RCTs with 4216 patients were in- eluded in this review and 16 comparisons from 13 trials were involved for analysis. The pooled analysis revealed no significant difference between long-term and short-term duration [HR=0.99, 95% CI （0.89, 1.11）, P=-0.89]. Within the subgroup analysis, patients benefited from long-term instillations with a start regimen of one immediate instillation [HR=0.83, 95% CI （0.69, 1.00）, P=-0.05]. But patients were not suitable to receive long-term instillations with epirubicin （EPI） [HR=1.01, 95% CI （0.91, 1.13）, P=0.78] The progression rate was not reduced after long-term instillations [HR=0.96, 95% CI （0.66, 1.39）, P=0.82]. From our results, patients should not receive introvesical chemotherapy more than half a year. In contrast, patients with one immediate instillation are preferred to have a long-term duration at least one year. Long-term instillations can not reduce the progression rate. 展开更多
关键词 duration non-muscle-mvaslve bladder cancer intravesical administration adjuvant chemotherapy meta-analysis
暂未订购 下载PDF
Novel coumarone-derived(S,E)-4-(4-fluorobenzylidene)-3-phenylchroman-3-ol inhibits muscle-invasive bladder cancer cells by repressing the S and G2 cell cycle phases 认领 引用
10
作者 Xin-Yi Han A-Dan Li +3 位作者 Fa-Ying Zhou Chao Li Guo-Du Liu Yong Xia 《Precision Medicine Research》 2023年第2期8-15,共8页
Background:This study aimed to select compounds with unique inhibitory effects on muscle-invasive bladder cancer(MIBC)from coumarone derivatives with similar parent nuclear structures and to reveal their tumor-suppres... Background:This study aimed to select compounds with unique inhibitory effects on muscle-invasive bladder cancer(MIBC)from coumarone derivatives with similar parent nuclear structures and to reveal their tumor-suppressive effects using various approaches.Methods:Bladder cancer cell lines SW780 and T24,as well as human normal bladder epithelial cell line SV-HUC-1 were selected as the study model,and these urinary system cells were co-incubated with various concentrations of(S,E)-4-(4-methylbenzylidene)-3-phenylchroman-3-ol,(S,E)-4-(4-isocyanobenzylidene)-3-phenylchroman-3-ol,(S,E)-4-(4-fluorobenzylidene)-3-phenylchroman-3-ol(FPO),and(S,E)-3-phenyl-4-(4-(trifluoromethoxy)benzylidene)chroman-3-ol.Cell activity was detected using cell counting kit-8.FPO showed the strongest inhibitory effect on MIBC cells;therefore,it was selected for further experiments.We monitored the FPO-induced T24 cell morphological changes with an inverted microscope.The FPO-inhibited migration of T24 cells was examined using a cell scratch assay.We detected the clonogenic ability of T24 cells through a clone formation test and evaluated their proliferative ability using a 5-ethynyl-2’-deoxyuridine fluorescence staining kit.The inhibitory effect of FPO against the cell cycle was monitored using flow cytometry,and its suppressive effect on the DNA replication ability of T24 cells was detected using double fluorescence staining(Ki67 and phalloidin).Results:Among the four candidate coumarone derivatives,FPO showed the most significant inhibitory effect on MIBC cells and was less toxic to normal urothelial cells.FPO inhibited T24 cell growth in time and dose-dependent manners(the half-inhibitory concentration is 8μM).FPO significantly repressed the proliferation,migration,and clonogenic ability of bladder cancer T24 cells.Cell mobility was significantly inhibited by FPO:30μM FPO almost completely repressed migration occurred at after 24 h treatment.Moreover,FPO significantly suppressed the clonogenicity of bladder cancer cells in a dose-dependent manner.Mechanistically,FPO targeted the cell cycle,arresting the S and G2 phases on bladder cancer T24 cells.Conclusion:We discovered a novel anticancer chemical,FPO,and proposed a potential mechanism,through which it suppresses MIBC T24 cells by repressing the cell cycle in the S and G2 phases.This study contributes to the development of novel anticancer drugs for MIBC. 展开更多
关键词 muscle-invasive bladder cancer cell proliferation cell cycle DNA replication coumarone derivate
暂未订购 下载PDF
Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer 认领 引用 被引量：3
11
作者 Niloufar Ahmadi Hamid Shafee Emaduddin Moudi 《Asian Journal of Urology》 CSCD 2024年第4期625-632,共8页
Objective:Non-muscle-invasive bladder cancer (NMIBC) remains a common challenge in uro-oncology with conflicting reports on recurrence risk. This study aimed to elucidate the recurrence rate of NMIBC in the Cancer Cli... Objective:Non-muscle-invasive bladder cancer (NMIBC) remains a common challenge in uro-oncology with conflicting reports on recurrence risk. This study aimed to elucidate the recurrence rate of NMIBC in the Cancer Clinic of Shahid Beheshti Hospital in Iran and to investigate related parameters affecting recurrence risk.Methods:The data of 143 patients with NMIBC, who underwent treatment between January 2017 and January 2020 and were followed up from the initial transurethral resection of bladder tumor until November 30, 2020 in our institution, were retrospectively assessed. The Cox regression analysis and Kaplan–Meier plot of recurrence-free survival were used to determine independent contributing factors for tumor recurrence.Results:Among patients with NMIBC, 83.9% were male, and 16.1% were female, with a mean age of 64.4 (standard deviation [SD] 12.9) years. During the follow-up, 71 (49.7%) patients showed tumor recurrence, with a mean recurrence time of 11.5 (SD 6.9) months. In the Chi-square test or Fisher's exact test, the age (≥65 years) (p=0.037), obesity (body mass index ≥30 kg/m2) (p=0.004), no diabetes mellitus (p=0.005), smoking (current or former smoker) (p=0.001), immediate perfusion therapy (p=0.035), number of tumors (>3) (p<0.001), and tumor stage (Ta, T1, and Tis) (p=0.001) had independent significant effects on the recurrence of NMIBC. The multivariate Cox regression analysis indicated that preoperative obesity (hazards ratio [HR] 7.90;95% confidential interval [CI] 4.01–15.55;p<0.001), current or former smoking (HR 1.85;95% CI 1.07–3.20;p=0.027), and a high-grade tumor (HR 4.03;95% CI 1.59–10.25;p=0.003) were significant predictors of tumor recurrence. The Kaplan–Meier plot of recurrence-free survival showed that obesity (log-rank p<0.001), current or former smoking (log-rank p=0.001), and a high-grade tumor (log-rank p=0.006) were associated with a shorter time interval until the first tumor recurrence.Conclusion:The study found a high recurrence rate of NMIBC in Iran from January 2017 to January 2020, with the obesity, smoking history, and the high-grade tumor as contributing factors. 展开更多
关键词 Bladder cancer Non-muscle-invasive Prediction Recurrence
暂未订购 下载PDF
Clinicopathological Analysis of Patients with Nonmuscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy 认领 引用
12
作者 Naotaka Nishiyama Hiroshi Kitamura +4 位作者 Masatoshi Mutoh Masahiro Yanase Hiroyuki Iwaki Tadashi Hasegawa Taiji Tsukamoto 《Surgical Science》 2012年第7期347-352,共6页
Objectives: Surgical specimens obtained at the time of the last transurethral resection of bladder tumor (TURBT) for patients with nonmuscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy were retros... Objectives: Surgical specimens obtained at the time of the last transurethral resection of bladder tumor (TURBT) for patients with nonmuscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy were retrospectively evaluated in order to investigate the relationship between pathological variation and upstaging of NMIBC. Methods and Materials: Twenty patients (19 men, 1 woman;aged 69.4 ± 12.1 (mean ± SD) years) diagnosed with NMIBC underwent radical cystectomy during follow-up. Results: Five of the 20 patients (25%) had pathological upstaging in the radical cystectomy specimens. There was a statistical association between pathological upstaging and cancer death (p = 0.002). There were three patterns of pathological variation in the upstaged specimens: 1) in patients with BCG-resistant NMIBC, urothelial carcinoma invaded through the lamina propria;2) urothelial carcinoma showed diffuse invasion beyond the deep lamina propria, and the cancer cells had infiltrated as single cells and formed nodules;3) TURBT specimens showed a micropapillary variant. Conclusions: Since these pathological variations correlated with pathological upstaging, they may provide an indication for cystectomy in NMIBC patients. 展开更多
关键词 Clinicopathological Examination Nonmuscle-Invasive Bladder Cancer Radical Cystectomy Pathological Upstaging
暂未订购 下载PDF
Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers:An open-label,prospective,single-center,randomized,controlled and parallel-group pilot study 认领 引用
13
作者 Paolo Casale Rodolfo Hurle +11 位作者 Nicolo M Buffi Giovanni Lughezzani Alberto Saita Vittorio Fasulo Marco Paciotti Alessio Benetti Roberto Peschechera Luisa Pasini Silvia Zandegiacomo Paola Arena Alessandro Uleri Massimo Lazzeri 《Current Urology》 CAS CSCD 2026年第2期117-124,共8页
Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has... Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome,its effcacy in patients who undergo TURBT is unknown.This study aimed to present the results of a prospective,randomized,controlled,clinical pilot study on the safety and clinical performance of Hydeal Cyst(Fidia Farmaceutici S.p.A.,Italy),a device formulated to provide progressive,long-lasting intravesical release of hyaluronic acid.Materials and methods:Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT.Of the 47 patients who completed the investigation,25 participants received 2 postoperative intravesical instillations with Hydeal Cyst.The effcacy of Hydeal Cyst on storage LUTS,pain,urinary symptoms,and patients'quality of life was evaluated using validated questionnaires.Results:Although the overall LUTS were similar in the 2 experimental groups,lower micturition frequency and fewer daytime micturitions were observed in patients treated with Hydeal Cyst.These patients also showed a signifcant reduction in pain(p=0.03)3 days after catheter removal and better quality of life at the end of the study.The device was well tolerated,with no treatment-emergent adverse events of severe intensity.Conclusion:The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of Hydeal Cyst,supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT. 展开更多
关键词 Transurethral resection Lower urinary tract symptoms Nonmuscle invasive bladder cancer Hyaluronic acid Pain Quality of life
The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling 认领 引用 被引量：1
14
作者 Xiaoyu Zhang RenFei Zong +9 位作者 Yan Sun Nan Chen Kunyao Zhu Hang Tong Tinghao Li Junlong Zhu Zijia Qin Linfeng Wu Aimin Wang Weiyang He 《Oncology Research》 SCIE 2026年第2期512-530,共19页
Objective:While cisplatin-based chemotherapy is pivotal for advanced bladder cancer,acquired resistance remains a major obstacle.This study investigates key molecular drivers of this resistance and potential reversal ... Objective:While cisplatin-based chemotherapy is pivotal for advanced bladder cancer,acquired resistance remains a major obstacle.This study investigates key molecular drivers of this resistance and potential reversal strategies.Methods:We established GC(Gemcitabine and Cisplatin)-resistant T24-R and UC3-R cell lines from T24 and UM-UC-3(UC3)cells.Transcriptomic and proteomic analyses identified differentially expressed molecules.Apoptosis and cell viability were assessed by flow cytometry and CCK-8(Cell Counting Kit-8)assays,while RT-qPCR(Reverse Transcription Quantitative Polymerase Chain Reaction)and Western blot analyzed gene and protein expression.Immunofluorescence evaluated FAK(Focal Adhesion Kinase)phosphorylation,and a xenograft mouse model validated the findings in vivo.Results:Integrated transcriptomic and proteomic analysis identified FN1(fibronectin)as a consistently upregulated top candidate in resistant cells(T24-R transcript log2FC=2.8,protein log2FC=0.9;UC3-R transcript log2FC=3.7;all p<0.001).Knockdown of FN1 reduced chemoresistance(Resistance Index:5.2 in T24-R and 2.0 in UC3-R cells,p<0.001)and enhanced apoptosis(approximately 4.5-fold in T24-R and 7.5-fold in UC3-R,p<0.001).ITGB4(Integrin Subunit Beta 4)was upregulated in resistant cells(transcript log2FC:4.2 in T24-R and 3.03 in UC3-R;protein log2FC:0.67 in T24-R;all p<0.01).Critically,ITGB4 knockdown abolished the chemoresistance promoted by exogenous FN1,which was associated with increased FAK(Y397)phosphorylation.Conclusion:Our results demonstrate that the FN1-ITGB4 axis drives chemoresistance in bladder cancer via FAK signaling.Targeting this axis represents a promising strategy to overcome chemoresistance. 展开更多
关键词 Bladder cancer chemoresistance fibronectin focal adhesion kinase integrin subunit beta 4 gemcitabine and cisplatin
暂未订购 下载PDF
Tracing the evolution and progression of bladder cancer from epigenetic origins to clinical early diagnostics 认领 引用
15
作者 Zilin Xu Shenjuan Li +7 位作者 Wan Xiang Hongwei Peng Mengxue Yu Kaiyu Qian Fangjin Chen Lingao Ju Yu Xiao Gang Wang 《Oncology and Translational Medicine》 CAS CSCD 2026年第3期128-131,共4页
1.Introduction Bladder cancer(BLCA),particularly the muscle-invasive(MIBC)subtype,represents one of the most challenging malignancies of the urinary tract and poses substantial difficulties in clinical management.Alth... 1.Introduction Bladder cancer(BLCA),particularly the muscle-invasive(MIBC)subtype,represents one of the most challenging malignancies of the urinary tract and poses substantial difficulties in clinical management.Although therapeutic advances such as neoadjuvant chemotherapy and immune checkpoint inhibitors have improved patient outcomes,pronounced intratumoral heterogeneity(ITH)results in considerable inter-individual variability in treatment response,contributing to treatment failure and disease recurrence.[1]Consequently,a deeper understanding of tumor evolution and precise tumor classification is critical for identifying effective therapeutic targets and diagnostic or prognostic biomarkers. 展开更多
关键词 neoadjuvant chemotherapy epigenetic origins bladder cancer intratumoral heterogeneity ith results immune checkpoint inhibitors bladder cancer blca particularly muscle invasive bladder cancer therapeutic advances
暂未订购 下载PDF
Bladder preservation alternatives in non-metastatic muscle-invasive bladder tumor:A systematic review and meta-analysis 认领 引用
16
作者 Diego Parrao Nemecio Lizana +5 位作者 Catalina Saavedra Valentina Fernández Carolina B.Lindsay Matías Larrañaga Mario I.Fernández Juan Cristóbal Bravo 《Asian Journal of Urology》 CAS CSCD 2025年第3期309-319,共11页
Objective:To systematically review the most recent scientific literature regarding modern strategies for organ preservation in the treatment of non-metastatic muscle-invasive bladder cancer.Methods:Literature search w... Objective:To systematically review the most recent scientific literature regarding modern strategies for organ preservation in the treatment of non-metastatic muscle-invasive bladder cancer.Methods:Literature search was made using PubMed,Google Scholar,EMBASE,Wiley Library,and ClinicalTrials.gov following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.The primary outcome was 5-year overall survival rate,which was addressed by a systematic review and meta-analysis.The risk of bias and quality of evidence were assessed according to the Cochrane Collaboration and the Grading of Recommendations,Assessment,Development and Evaluation system.Results:The evidence is consistent in showing that 5-year survival of trimodality therapy is similar to radical cystectomy in selected patients,ranging between 29%and 73%.Patients undergoing bladder-sparing therapy were found to have better outcomes in terms of quality of life and sociability than those undergoing radical cystectomy.Immunotherapy is establishing itself as a strategy for organ-preservation treatment,showing complete response rates between 42%and 100%.However,most of these results have been obtained from ongoing clinical trials.Furthermore,there are still no studies comparing the efficacy among the different available therapies.Conclusion:Although radical cystectomy remains the gold standard treatment for muscle-invasive bladder cancer,its significant morbidity has prompted the exploration of alternative therapies.In this context,bladder preservation therapies,though supported by limited literature,emerge as a potential alternative that could offer comparable oncological outcomes in selected patients. 展开更多
关键词 Muscle-invasive bladder cancer Trimodality therapy Immunotherapy Bladder-sparing
暂未订购 下载PDF
Bladder cancer patients hospitalized in a medicine ward including three fuo cases following bacillus calmette-guérin immunotherapy 认领 引用
17
作者 George Liatsos Kalliopi Zioutou +3 位作者 Konstantinos Avramidis Konstantinos Vamvakaris Maria Potamiti-Komi Dimitrios Vassilopoulos 《The Canadian Journal of Urology》 SCIE 2026年第2期349-360,共12页
Objectives:Bladder cancer(BC)is a prevalent malignancy with evolving treatment strategies and an increasingly aging patient population,resulting in a growing and complex burden of hospitalizations that extends beyond ... Objectives:Bladder cancer(BC)is a prevalent malignancy with evolving treatment strategies and an increasingly aging patient population,resulting in a growing and complex burden of hospitalizations that extends beyond urological care and remains insufficiently characterized in real-world Internal Medicine settings.This study aimed to analyze the clinical data and outcomes for patients with BC admitted to the medicine ward.Additionally,this research presents three cases of fever of unknown origin,which all exhibited identical clinical and laboratory findings but ultimately resulted in different disease diagnoses.Methods:This retrospective case-series study included all adult patients with BC admitted to the Internal Medicine ward of a tertiary referral hospital between 1 January 2020,and 31December 2024.Data acquisition was performed through a systematic search of electronic discharge records using the ICD-10 code C67.Data recording involved detailed review of electronic medical records to collect demographic characteristics,clinical history,cancer-related treatments,causes of hospitalization,and outcomes.Three patients previously treated with intravesical Bacillus Calmette–Guérin(iBCG)who presented with fever of unknown origin were analyzed in detail.Data analysis comprised descriptive statistics and comparative testing using Fisher’s exact test and unpaired two-tailed Student’s t-test,with p<0.05 considered statistically significant.Results:We identified 77 hospitalizations among 67 BC patients who were predominantly male,with a mean age of 75.2.A high prevalence of metabolic syndrome comorbidities and chronic obstructive pulmonary disease was documented.In addition,31.1%of patients had metastatic BC,22.9%had a second malignancy,49.2%had undergone urological surgeries,and 38%had received chemotherapy or immunotherapy other than iBCG.The most common causes of hospitalization were infections,anemiaransfusions,a newly diagnosed metastatic disease,and acute renal failure.The mortality in this cohort was high(17%),with the leading cause of death again being an infection.Among patients who had previously received BCG immunotherapy,three cases of fever of unknown origin were noticed,and despite identical clinical settings,they were identified with different diseases[metastatic disease,infection caused by Bacillus Calmette-Guérin(BCGitis),and Hodgkin’s lymphoma],necessitating individualized therapeutic medications.Conclusions:BC patients in the Internal Medicine unit are generally older adults,often dealing with several chronic conditions and a considerable cancer burden.They are predominantly admitted due to infections,which points to the urgent need for effective infection prevention strategies for this vulnerable population.When BC patients have a fever lasting more than seven days following BCG instillation,which is the maximum duration for self-limited adverse events to occur,regardless of whether an antibiotic regimen has been prescribed,they should consult an internal medicine department for further evaluation. 展开更多
关键词 Bladder cancer intravesical BCG BCGitis fever of unknown origin hospitalization hodgkin’s lymphoma
暂未订购 下载PDF
Development and validation of a survival nomogram for muscle-invasive bladder cancer in the elderly: using competing risk models and propensity matching to apply the prediction tool 认领 引用
18
作者 Chenghao Zhanghuang Zhaoxia Zhang +8 位作者 Hongchao Jiang Jinkui Wang Zhigang Yao Fengming Ji Chengchuang Wu Zhen Yang Yucheng Xie Haoyu Tang Bing Yan 《Journal of Cancer Metastasis and Treatment》 CAS 2023年第1期576-592,共17页
Aim:Patients with muscle-invasive bladder cancer(MIBC)have a low survival rate,with a 5-year survival of approximately 45%,regardless of the treatment received.The risk of death within 5 years after radical cystectomy... Aim:Patients with muscle-invasive bladder cancer(MIBC)have a low survival rate,with a 5-year survival of approximately 45%,regardless of the treatment received.The risk of death within 5 years after radical cystectomy in patients with MIBC remains as high as 60%.Over 80%of patients with bladder cancer are over 65.Therefore,identifying prognostic correlates associated with radical cystectomy in older patients with MIBC could improve survival rates.In addition,radiotherapy and chemotherapy are particularly important as adjuvant treatments for MIBC patients undergoing radical cystectomy.Therefore,this study aimed to find risk factors for cancer-specific survival(CSS)and overall survival(OS)after radical cystectomy in elderly MIBC patients.The difference in survival between radiotherapy and chemotherapy was analyzed by Kaplan-Meier(K-M)curves to provide theoretical support for whether radiotherapy is recommended for such patients.Methods:Patients 65 or older diagnosed with MIBC with radical cystectomy between 2004-2018 were obtained from the Surveillance,Epidemiology,and End Results(SEER)database.2004-2015 patients were subjected to column line plot production and internal validation,and 2016-2018 patients were subjected to external temporal validation.A single-factor COX regression model was first used to screen for prognostic correlates.Then a multi-factor COX regression model was used to screen for independent risk factors.A nomogram was constructed by using independent risk factors.The accuracy and reliability of the nomogram were examined using calibration curves,consistency index(C-index),and area under subjects(AUC)as operational characteristic curves.Decision curve analysis(DCA)was performed to evaluate the clinical value of the prediction model.Results:A total of 11,557 patients were included in this study,divided into training set(N=4,712),validation set(N=4,810)and external validation set(N=2,035).Multivariate COX regression models showed that chemotherapy,radiotherapy,TNM stage,race,and age were independent risk factors for CSS and OS patients.We constructed a nomogram to predict CSS and OS in elderly MIBC patients undergoing radical cystectomy.The C-indexes were 0.692(95%CI:0.680-0.704)and 0.690(95%CI:0.678-0.702)for the CSS training and validation sets,respectively,and 0.674 for the OS training and validation sets(95%CI:0.664-0.684)and 0.672(95%CI:0.662-0.682)for the OS training and validation sets,respectively.The C-index of the external validation set CSS was 0.731(95%CI:709-0.753),and that of OS was 0.721(95%CI:0.701-0.741),indicating that the nomogram prediction model has good discriminative power.The calibration curves and AUC also suggested that the nomogram had good accuracy and discrimination.In addition,the KM curves of propensity-matched pre-and post-radiotherapy showed that radiotherapy was detrimental to patient survival.Meanwhile,chemotherapy favored OS and short-term CSS but not long-term CSS.Conclusions:We established a nomogram to predict the CSS and OS in elderly MIBC patients undergoing radical cystectomy.After internal cross-validation and external validation,the nomogram prediction model showed good accuracy and reliability,and the DCA results showed that the nomogram has good clinical value.In addition,this study gave good suggestions on whether radiotherapy or chemotherapy is necessary for radical cystectomy in elderly MIBC patients. 展开更多
关键词 Muscle-invasive bladder cancer(MIBC) nomogram OS CSS SEER radiotherapy chemotherapy
Germinal Center–Like Tertiary Lymphoid Structures Mark Immune Responsiveness and Enable Checkpoint Immunotherapy in Bladder Cancer 认领 引用
19
作者 Zhihao Yin Xi Zhen +13 位作者 Haonan Li Haiqiang Duan Xiaowei Hu Tianxi Yu Qing Shi Ziyi Liu Yaowei Li Peng Zhang Peng Dai Meihui Zhao Ziqi Wang Changfu Li Di Wang Zhichao Tong 《Oncology Research》 SCIE 2026年第7期595-624,共30页
Backgrounds:Tertiary lymphoid structures(TLSs)are increasingly recognized as modulators of anti-tumor immunity,yet their clinical relevance in bladder cancer remains incompletely understood,partly owing to heterogenei... Backgrounds:Tertiary lymphoid structures(TLSs)are increasingly recognized as modulators of anti-tumor immunity,yet their clinical relevance in bladder cancer remains incompletely understood,partly owing to heterogeneity in their maturation states.Here,we demonstrate that germinal center(GC)–like TLS maturity,rather than TLS presence alone,is closely associated with immune activation and therapeutic response to Programmed Death-Ligand 1(PD-L1)blockade in bladder cancer.The objective of this study was to systematically investigate the clinical significance,biological function,and therapeutic potential of tertiary lymphoid structure(TLS)maturation in bladder cancer.Specifically,we aimed to determine whether GC-like TLS maturity provides prognostic and predictive value beyond TLS presence alone,to elucidate the immune programs and tumor microenvironment remodeling associated with TLS maturation,and to explore whether TLS maturation can be therapeutically induced to enhance responsiveness to PD-L1 blockade.Methods:We performed an integrative analysis combining multi-cohort transcriptomics,spatially resolved histopathology,single-cell RNA sequencing,and functional murine experiments.TLS maturation states were defined using gene-expression–based GC-like TLS signatures and validated through multiplex immunohistochemistry.Clinical relevance was assessed in public immunotherapy cohorts and an independent neoadjuvant PD-L1–treated muscle-invasive bladder cancer(MIBC)cohort.Tumor immune microenvironment remodeling and chemokine-mediated cellular crosstalk were analyzed using deconvolution,Weighted Gene Co-expression Network Analysis(WGCNA),and CellChat.The therapeutic inducibility of TLS maturation was examined using a lymphotoxin-βreceptor(LTβR)agonist in combination with PD-L1 blockade in a syngeneic bladder cancer model.Results:Across multiple transcriptomic cohorts,tumors enriched for GC-like TLS signatures exhibited significantly prolonged survival and higher objective response rates to anti–PD-L1 therapy,whereas less mature TLS phenotypes showed no consistent association with clinical association.These observations were independently validated in a neoadjuvant PD-L1–treated muscle-invasive bladder cancer cohort,in which high mature TLS density was associated with major pathological response and prolonged event-free survival,outperforming PD-L1 expression.Integrative histopathological and transcriptomic analyses indicated that GC formation marks a functional transition linking humoral immune programs with cytotoxic effector activity and shaping a memory-prone,pro-inflammatory tumor immune microenvironment.Chemokine signaling via the CC chemokine ligand 21(CCL21)–C-C chemokine receptor type 7(CCR7)and C-X-C motif chemokine ligand 12(CXCL12)–C-X-C chemokine receptor type 4(CXCR4)axes was strongly associated with TLS maturation and spatial organization.Finally,in a syngeneic bladder cancer model,pharmacological activation of lymphotoxin-βreceptor signaling promoted TLS maturation and enhanced the antitumor efficacy of PD-L1 blockade.Conclusions:Together,these findings suggest that GC-like TLS maturity represents a clinically relevant biomarker and a potential therapeutic entry point for precision immunotherapy in bladder cancer.Therapeutic strategies that promote TLS maturation may convert immune-cold tumors into checkpoint-responsive states,providing a mechanistically grounded precision immunotherapy approach. 展开更多
关键词 Tertiary lymphoid structures bladder cancer germinal center(GC)–like tertiary lymphoid structure tumor microenvironment programmed death-ligand 1
暂未订购 下载PDF
Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: a propensity score-matched study 认领 引用 被引量：1
20
作者 Waichan Lok Jiapeng Zhang +4 位作者 Xiaonan Zheng Tianhai Lin Hang Xu Ping Tan Qiang Wei 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第9期1067-1073,共7页
Background:Studies have classified muscle-invasive bladder cancer(MIBC)into primary(initially muscle-invasive,PMIBC)and secondary subtypes(initially non-muscle-invasive but progresses,SMIBC),for which controversial su... Background:Studies have classified muscle-invasive bladder cancer(MIBC)into primary(initially muscle-invasive,PMIBC)and secondary subtypes(initially non-muscle-invasive but progresses,SMIBC),for which controversial survival outcomes were demonstrated.This study aimed to compare the survival outcomes between PMIBC and SMIBC patients in China.Methods:Patients diagnosed with PMIBC or SMIBC at West China Hospital from January 2009 to June 2019 were retrospectively included.Kruskal-Wallis and Fisher tests were employed to compare clinicopathological characteristics.Kaplan-Meier curves and Cox competing proportional risk model were used to compare survival outcomes.Propensity score matching(PSM)was employed to reduce the bias and subgroup analysis was used to confirm the outcomes.Results:A total of 405 MIBC patients were enrolled,including 286 PMIBC and 119 SMIBC,with a mean follow-up of 27.54 and 53.30 months,respectively.The SMIBC group had a higher proportion of older patients(17.65%[21/119]vs.9.09%[26/286]),chronic disease(32.77%[39/119]vs.22.38%[64/286]),and neoadjuvant chemotherapy(19.33%[23/119]vs.8.04%[23/286]).Before matching,SMIBC had a lower risk of overall mortality(OM)(hazard ratios[HR]0.60,95%confidence interval[CI]0.41-0.85,P=0.005)and cancer-specific mortality(CSM)(HR 0.64,95%CI 0.44-0.94,P=0.022)after the initial diagnosis.However,higher risks of OM(HR 1.47,95%CI 1.02-2.10,P=0.038)and CSM(HR 1.58,95%CI 1.09-2.29,P=0.016)were observed for SMIBC once it became muscle-invasive.After PSM,the baseline characteristics of 146 patients(73 for each group)were well matched,and SMIBC was confirmed to have an increased CSM risk(HR 1.83,95%CI 1.09-3.06,P=0.021)than PMIBC after muscle invasion.Conclusions:Compared with PMIBC,SMIBC had worse survival outcomes once it became muscle-invasive.Specific attention should be paid to non-muscle-invasive bladder cancer with a high progression risk. 展开更多
关键词 Mortality Muscle-invasive bladder cancer Propensity score Survival
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 250 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈